The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation.
In conclusion, the EGFR/CD13 bi-targeted fusion protein ER(Fv)‑LDP-NGR displays multi-functional characteristics, acting on both cancer cells and endothelial cells. It might be an effective agent for targeted cancer therapy.
PMID: 29130101 [PubMed - in process]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Adenocarcinoma | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Depression | Study